Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical Management Changes After EUS for Incidental Pancreatic Cysts: A Single-Center Experience.

Pancreas·2026

Same author

Comparison of thrombosis risk in patients undergoing purified and non-purified islet cell transplantation.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2025

Same author

Quality of Life Following Total Pancreatectomy With Islet Autotransplantation: A Patient Experience Survey.

Pancreas·2024

Same author

Surveillance With Serial Imaging and CA 19-9 Tumor Marker Testing After Resection of Pancreatic Cancer: A Single-Center Retrospective Study.

American journal of clinical oncology·2023

Same author

CT characterization of retractor related liver injuries after pancreaticoduodenectomy: Retrospective analysis of a single institution experience.

Clinical imaging·2023

Same author

Effectiveness of Intraoperative Versus Dedicated Islet Cell Laboratory Isolation for Total Pancreatectomy With Islet Autotransplant.

Transplantation direct·2022

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Adjuvant and neoadjuvant therapy for primary GIST.

Burton L Eisenberg¹, Kerrington D Smith

¹Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Section of Surgical Oncology, Lebanon, NH, USA. Burton.L.Eisenberg@Dartmouth.edu

Cancer Chemotherapy and Pharmacology

|December 1, 2010

Summary

Adjuvant therapy helps extend disease-free survival for primary gastrointestinal stromal tumors (GIST). Neoadjuvant therapy may offer benefits like tumor downsizing, but requires further study.

Related Experiment Videos

Last Updated: Jun 6, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Area of Science:

Oncology
Surgical Oncology
Gastroenterology

Background:

Adjuvant therapy for primary gastrointestinal stromal tumors (GIST) improves disease-free survival.
Risk factors for GIST recurrence include tumor size, location, and mitotic rate, guiding adjuvant therapy decisions.
Neoadjuvant therapy with tyrosine kinase inhibitors is being explored for primary GIST.

Purpose of the Study:

To review the established benefits of adjuvant therapy in primary GIST.
To discuss the potential advantages and current limitations of neoadjuvant therapy in primary GIST.
To highlight the need for further clinical evaluation of neoadjuvant approaches.

Main Methods:

Literature review of adjuvant and neoadjuvant therapy in GIST.
Analysis of risk factors influencing GIST recurrence and treatment selection.
Discussion of theoretical benefits of neoadjuvant tyrosine kinase inhibition.

Main Results:

Adjuvant therapy is a proven method for extending disease-free survival in primary GIST.
Tumor size, location, and mitotic rate are key predictors of GIST recurrence.
Neoadjuvant therapy may facilitate less morbid surgery and reduce intraoperative risks, though not yet standard care.

Conclusions:

Adjuvant therapy remains a cornerstone in managing primary GIST post-resection.
Neoadjuvant therapy presents a promising, albeit unproven, strategy for optimizing surgical outcomes in GIST.
Larger clinical trials are necessary to validate the efficacy and safety of neoadjuvant tyrosine kinase inhibition for primary GIST.